Trials / Completed
CompletedNCT02565628
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 45 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess safety, tolerability and pharmacokinetic data for multiple doses of PF-06669571 in subjects with idiopathic Parkinson's disease. In addition, this study will assess whether PF-06669571 is able to demonstrate superior efficacy compared with placebo in the treatment of the motor symptoms of idiopathic Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06669571 | 1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2015-11-16
- Primary completion
- 2016-05-13
- Completion
- 2016-05-13
- First posted
- 2015-10-01
- Last updated
- 2023-07-24
- Results posted
- 2017-08-07
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02565628. Inclusion in this directory is not an endorsement.